Abstract
Background
Although transurethral resection (TUR) is the standard treatment for non-muscle-invasive bladder tumors, 40–80% of tumors recur in spite of complete resection.
Objective
To evaluate the efficacy, dose effectiveness and safety of early short-duration intravesical instillation therapy using epirubicin (EPI) administered immediately after TUR and on the next day following TUR.
Patients and methods
Between 1995 and 2001, 303 patients with Ta and T1 non-muscle-invasive bladder carcinoma were enrolled in this study. Patients were randomized into three groups. Group A patients were treated with two intravesical infusions of EPI 20 mg/40 ml saline immediately after TUR and within 24 h. Group B patients were treated with EPI 50 mg/100 ml on the same schedule as group A. Group C patients were treated by TUR alone as a control group. The primary endpoint was a duration to the first recurrence.
Results
Of the 303 patients, 79 in Group A, 84 in Group B, and 77 in Group C could be evaluated for recurrence. Median follow-up was 44 months. Median recurrence-free survival durations for Groups A, B, and C were 24, 38, and 13 months, respectively. The difference between Groups B and C was statistically significant (p = 0.04). Adverse reactions related to instillation were observed in about 30% of the patients. These reactions included micturition pain and frequency. These toxicities were mild and transient.
Conclusion
Intravesical instillation of EPI 50 mg twice within 24 h after TUR was effective as prophylactic therapy for non-muscle-invasive bladder cancer with tolerable toxicity problems.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Witjes JA (2009) Topic issue on new treatments in bladder cancer. World J Urol 27:285–287
Lamm DL, Blumenstein BA, Crawford ED et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205–1209
Witjes JA, Meijden AP, Sylvester LC et al (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52:403–410
Okamura K, Ono Y, Kinukawa T et al (2002) Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94:2363–2368
Witjes JA, Hendricksen K (2008) Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53:45–52
Hinotsu S, Akaza H, Isaka S et al (2002) Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer. Fifth Study of the Japanese Urological Cancer Research Group for Adriamycin/Farmorubicin. Gan To Kagaku Ryoho 29:73–80
Ali-el-Dein B, Nabeeh A, el-Baz M et al (1997) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79:731–735
Melekos MD, Dauaher H, Fokaefs E, Barbalias G (1992) Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol 147:371–375
Oosterlinck W, Kurth KH, Schröder F et al (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749–752
Gudjónsson S, Adell L, Merdasa F et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomized multicentre study. Eur Urol 55(4):773–780
Hendricksen K, Witjes WP, Idema JG et al (2008) Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53:984–991
Kuroda M, Niijima T, Kotake T et al (2004) Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer—The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 45:600–605
Hameed A, Sezian N, Thwaini A (2007) Bladder contracture: review for intravesical bacillus Calmette-Guerin complication. Can J Urol 14:3745–3749
Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95
Shelley MD, Wilt TJ, Court J et al (2004) Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93:485–490
Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67:1216–1223
Hinotsu S, Akaza H, Ohashi Y, Kotake T (1999) Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86:1818–1826
Kaasinen E, Rintala E, Hellström P et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167–174
Acknowledgments
This study was conducted for the Okayama Urological Research Group at the following institutions: Okayama University, National Okayama Medical Center, National Iwakuni Medical Center, Hiroshima City Hospital, Kagawa Prefectural Central Hospital, Okayama Central Hospital, Tsuyama Central Hospital, Mitoyo General Hospital, Kure Kyosai hospital, Mihaya Red-cross hospital, Fukuyama Citizen’s hospital, Kurashiki Adult disease Hospital, Okayama Red-cross Hospital, Okayama city hospital, Okayama Rosai Hospital, Tamano Citizen’s hospital, Tottori Municipal Hospital, Takinimiya General hospital, Onomichi Citizen’s Hospital, Kochi Medical Center, Niihama Jyuzen Hospita,l Syuso General Hospital, Kagawa Rosai Hospital, Riturin Hospital, and Konko Hospital.
Conflict of interest statement
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the Okayama Urological Research Group (OURG).
Rights and permissions
About this article
Cite this article
Saika, T., Tsushima, T., Nasu, Y. et al. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World J Urol 28, 413–418 (2010). https://doi.org/10.1007/s00345-009-0502-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-009-0502-1